X4 Pharmaceuticals, Inc (XFOR) earnings date, results and what the price requires

    Nasdaq · SEC CIK 0001501697 · SEC filings checked Oct 17, 2026

    Next report
    Nov 6, 2026
    Estimated from reporting history (92-day cycle, SEC 8-K item 2.02 results filings). Not confirmed.
    Last close
    $2.59
    Polygon.io daily close, Oct 16, 2026. End of day, not live.
    Trailing diluted EPS
    $1.27
    Sum of quarters ending Jun 30, 2026, Mar 31, 2026, Dec 31, 2025, Sep 30, 2025 · P/E 2.0

    Previous results (SEC filings)

    Quarter endedReportedRevenueNet incomeDiluted EPSSource
    Jun 30, 2026Aug 6, 2026$8.8M$-16.2M$-0.13Filing
    Mar 31, 2026May 6, 2026$2.7M$-20.2M$-0.16Filing
    Dec 31, 2025Mar 17, 2026$2.6M$-23.9M$2.25Filing
    Sep 30, 2025Nov 5, 2025$1.8M$-29.8M$-0.69Filing
    Jun 30, 2025Aug 8, 2025$2.0M$-25.7M$-3.47Filing
    Mar 31, 2025May 1, 2025$28.8M$282,000$0.04Filing
    Dec 31, 2024Mar 25, 2025$1.4M$-39.8M$-5.91Filing
    Sep 30, 2024Nov 13, 2024$560,000$-36.7M$-5.48Filing

    What would X4 Pharmaceuticals, Inc have to report for its valuation to change?

    At $2.59, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about -29.5% a year, to $0.22. On that path the next quarter needs diluted EPS near $-0.49, against $-0.69 in the quarter ended Sep 30, 2025.

    Are you considering buying, or do you already own shares?

    Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.

    ResultOriginalYours
    Required EPS growth / year-29.5%-29.5%
    EPS needed in final year$0.22$0.22

    Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.

    Prepare for earnings across my investments — $399/month

    Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. XFOR goes in with your buy-or-wait comparison and assumptions preserved.

    Start Desk — $399/month

    Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.